Matwings Technology is an AI-driven full-stack protein R&D platform company. It has built proprietary ultra-large-scale protein sequence datasets and label libraries unavailable elsewhere in the industry. On this foundation, the company developed a general large model for protein design, enabling precise engineering of functional proteins tailored directly to industrial demands.
Centered on its self-developed large protein model, Matwings Technology has built an AI full-stack protein R&D platform equipped with scientific research agents and automated experimental devices. The platform covers the complete workflow: market, literature and patent research, molecular design, lab-scale verification, pilot process optimization, and production scale-up. By deploying AI across industrial scenarios, the platform breaks the cognitive boundaries of human experts, enabling faster and better development of diverse biological products with proteins as the core building blocks, including innovative pharmaceuticals, wellness products, agricultural materials, functional foods, and bio-based materials.
This investment marks a key milestone in Pharmacare’s industrial investment layout and represents a major step in leveraging capital to empower the AI biotechnology innovation track. Matwings Technology chooses to partner with Pharmacare largely out of high recognition of Pharmacare’s profound industrial resources in healthcare, global commercialization capabilities, and philosophy of long-term value creation.
Going forward, both parties will fully leverage their respective core strengths. Drawing on mature experience and resources in global market channels and industrial ecosystems, Pharmacare will provide end-to-end support covering R&D through commercialization for Matwings Technology’s AI protein technologies. Matwings Technology, with its leading AI-driven full-stack protein R&D platform, will inject cutting-edge technological momentum into Pharmacare and accelerate breakthroughs in the application of functional proteins across innovative medicines, wellness, agriculture, biomaterials and other sectors.
Through in-depth collaboration and complementary resources, the two sides will jointly advance the translation of cutting-edge technologies from laboratories to global markets, delivering core driving force for transformation and progress within the life sciences sector.
